Literature DB >> 16416145

The market in diabetes.

Alexandra Hauber, Edwin A M Gale.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16416145     DOI： 10.1007/s00125-005-0108-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  11 in total

1.  The PROactive study: some answers, many questions.

Authors:  Hannele Yki-Järvinen
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

2.  Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute.

Authors:  Scott M Grundy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-11       Impact factor: 8.311

3.  The metabolic syndrome--a new worldwide definition.

Authors:  K George M M Alberti; Paul Zimmet; Jonathan Shaw
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

4.  Selling safety--lessons from muraglitazar.

Authors:  James M Brophy
Journal:  JAMA       Date:  2005-10-20       Impact factor: 56.272

Review 5.  Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

Authors:  J J Holst
Journal:  Diabetologia       Date:  2006-01-14       Impact factor: 10.122

6.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

Authors:  Jean-Pierre Després; Alain Golay; Lars Sjöström
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

7.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Authors:  John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

8.  Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.

Authors:  H-J Mest; R Mentlein
Journal:  Diabetologia       Date:  2005-03-16       Impact factor: 10.122

9.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

Review 10.  The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  R Kahn; J Buse; E Ferrannini; M Stern
Journal:  Diabetologia       Date:  2005-09       Impact factor: 10.122
View more
  12 in total

1.  Nice insulins, pity about the evidence.

Authors:  F Holleman; E A M Gale
Journal:  Diabetologia       Date:  2007-09       Impact factor: 10.122

2.  Collateral damage: the conundrum of drug safety.

Authors:  E A M Gale
Journal:  Diabetologia       Date:  2009-10       Impact factor: 10.122

3.  Trends in pharmaceutical expenditures: the impact on drug benefit design.

Authors:  LaFleur Joanne; Fish Leslie; Diana I Brixner
Journal:  Am Health Drug Benefits       Date:  2008-05

4.  The contralateral extremity has also benefit from the locally administered bone marrow-derived mononuclear cells and cord blood serum in diabetic ischemic wound healing.

Authors:  A Tulga Ulus; Ferda Alpaslan Pınarli; Devrim Sonmez; Ahmet Yesilyurt; Tuncay Delibasi
Journal:  Stem Cell Rev Rep       Date:  2014-02       Impact factor: 5.739

5.  Cost-effectiveness of insulin analogues for diabetes mellitus.

Authors:  Chris G Cameron; Heather A Bennett
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262

6.  Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.

Authors:  Dario Giugliano; Maria Ida Maiorino; Giuseppe Bellastella; Paolo Chiodini; Antonio Ceriello; Katherine Esposito
Journal:  Diabetes Care       Date:  2011-01-07       Impact factor: 19.112

Review 7.  Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.

Authors:  Brendan McIntosh; Chris Cameron; Sumeet R Singh; Changhua Yu; Tarun Ahuja; Nicky J Welton; Marshall Dahl
Journal:  Open Med       Date:  2011-03-01

8.  Modern insulins, old paradigms and pragmatism: choosing wisely when deciding how to treat type 1 diabetes.

Authors:  Beatriz D Schaan; Rafael Selbach Scheffel
Journal:  Diabetol Metab Syndr       Date:  2015-04-22       Impact factor: 3.320

Review 9.  Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom?

Authors:  Ofri Mosenzon; Itamar Raz
Journal:  Diabetes Care       Date:  2013-08       Impact factor: 19.112

10.  Stratified patient-centered care in type 2 diabetes: a cluster-randomized, controlled clinical trial of effectiveness and cost-effectiveness.

Authors:  Annabelle S Slingerland; William H Herman; William K Redekop; Rob F Dijkstra; J Wouter Jukema; Louis W Niessen
Journal:  Diabetes Care       Date:  2013-08-15       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.